Gemcitabine

  • #LGM Pharma is a Gemcitabine CAS# 95058-81-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 95058-81-4
  • AHFC code: 10:00.0
  • Synonyms: 2',2'-Difluorodeoxycytidine, 2'-Deoxy-2',2'-difluorocytidine, CCRIS 8984, DDFC, DFdC, DFdCyd, Folfugem, Gamcitabine, Gemcel, Gemcitabina, Gemcitabina [INN-Spanish], Gemcitabine, Gemcitabinum, Gemcitabinum [INN-Latin], GemLip, HSDB 7567, LY 188011, LY188011, NSC 613327, UNII-B76N6SBZ8R, Zefei,
  • ATC Code: L01BC05
  • Chemical Formula: C9-H11-F2-N3-O4
  • Molecular Weight: 263.1989
  • Assay/Purity: Typically NLT 98%
  • DrugBank: APRD00201
  • SMILES: c1cn(c(=O)nc1N)[C,H]2C([C,,H]([C,H](O2)CO)O)(F)F
  • InChl: 1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
  • PubChem: 60750
  • IUPAC: 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on

Additional Details

Indication:
Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
Pharmacodynamics:
Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine – which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand. It demonstrates dose-dependent synergistic activity with cisplatin in vitro. In vivo, gemcitabine showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Gemcitabine was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to gemcitabine 4 hours before cisplatin produced the greatest interaction.
Mode of Action:
Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA.Gemcitabine offers potent antitumor activity both in vitro and in vivo tumor models.
Metabolism:
Transformed via nucleoside kinases to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate. Can also undergo deamination via cytidine deaminase to an inactive uracil metabolite (dFdU). Within one week roughly 92 percent to 98 percent of the Gemcitabine dosage is recovered, almost entirely in the urine.
Toxicity:
Few toxicity concerns have emerged from studies of Gemcitabine. Though rare, pulmonary toxicities are possible with Gemcitabine use, however symptoms are telling and come with rapid onset. Commonly occurring side effects, documented in over 30 percent of patients include fever, flu-like symptoms, vomiting, nausea, extreme fatigue and low blood counts.
General Reference:
N Engl J Med 2010; 362:1273-1281April 8, 2010DOI: 10.1056/NEJMoa0908721The Lancet Oncology, 2015.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials